Search company, investor...

Vitae Pharmaceuticals

vitaepharma.com

Founded Year

2001

Stage

Acq - P2P | Acquired

Total Raised

$105.97M

Valuation

$0000 

Revenue

$0000 

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical stage biopharmaceutical company discovering and developing a portfolio of small molecule compounds that address disease areas, including: chronic kidney disease, diabetes, Alzheimer's disease and atherosclerosis. Vitae's lead compound, VTP-27999, is a potent and selective renin inhibitor offering the potential for superior renal protection in patients suffering from chronic kidney disease. Vitae's discovery platform has advantages in creating and analyzing drug candidates that meet pre-defined physicochemical and biochemical characteristics. The accuracy and speed of this system has enabled Vitae to solve challenging targets in multiple therapeutic areas, discovering and advancing attractive compounds in a rapid and highly capital efficient manner.

Headquarters Location

502 West Office Center Drive

Fort Washington, Pennsylvania, 19034,

United States

215-461-2000

Missing: Vitae Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Vitae Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Vitae Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Vitae Pharmaceuticals is included in 2 Expert Collections, including Diabetes.

D

Diabetes

1,903 items

B

Biopharma Tech

838 items

Vitae Pharmaceuticals Patents

Vitae Pharmaceuticals has filed 62 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Monoclonal antibodies
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/9/2020

12/27/2022

Transcription factors, Designer drugs, Intracellular receptors, Prodrugs, Cannabinoids

Grant

Application Date

9/9/2020

Grant Date

12/27/2022

Title

Related Topics

Transcription factors, Designer drugs, Intracellular receptors, Prodrugs, Cannabinoids

Status

Grant

Latest Vitae Pharmaceuticals News

Upadacitinib demonstrates fast, efficacious atopic dermatitis treatment

May 21, 2021

Disclosures: Guttman-Yassky reports she is a researcher or consultant for AbbVie, Anacor, AnaptysBio, Asana Biosciences, AstraZeneca, Botanix, Celgene, DBV, Dermira, Dr. Reddy’s Laboratory (Promius), DS Biopharma, Escalier Biosciences, Galderma, Glenmark, Innovaderm, Janssen, Kyowa Kirin, Leo Pharma, Lilly, Mitsubishi Tanabe Pharma, Novan, Novartis, Pfizer, Ralexar, Regeneron, Sanofi, GlaxoSmithKline, UCB and Vitae Pharmaceuticals. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Upadacitinib, an oral JAK inhibitor , was effective in treating moderate to severe atopic dermatitis in two phase 3 clinical trials. “Up to recently, we really didn’t have any safe oral medications to give our atopic dermatitis patients,” lead author Emma Guttman-Yassky, MD, PhD, Sol and Clara Kest Professor and chair of the Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, and first author of the study, told Healio. “Though dupilumab is a great biologic drug, some of our patients do not want an injection. We definitely need an oral medication that can control the disease and do so rapidly.” Upadacitinib, an oral JAK inhibitor, was effective in treating moderate to severe atopic dermatitis in two phase 3 clinical trials. The replicate, double-blind, multicenter, randomized, placebo-controlled Measure Up 1 and Measure Up 2 trials randomly assigned patients aged 12 to 75 years 1:1:1 to receive upadacitinib 15 mg, upadacitinib 30 mg or placebo once daily for 16 weeks. Emma Guttman-Yassky In the Measure Up 1 trial, 70% of the 15 mg treatment group achieved Eczema Area and Severity Index 75 at 16 weeks, while 80% of those in the 30 mg group and 16% of the placebo group met the same endpoint. The proportion of those achieving validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) response was 48% in the 15 mg group, 62% in the 30 mg group and 8% in the placebo group. Results were similar in the Measure Up 2 study, with EASI-75 response reached by 60% of the 15 mg group, 73% of the 30 mg group and 13% of the placebo group. The upadacitinib 15 mg group had vIGA-AD response in 39% of patients, while the 30 mg group had 52% and the placebo group had 5%. Secondary endpoints, which included EASI-90, EASI-100 and change in EASI score from baseline at week 16, as well as EASI-75 at week 2 and a four-point or greater improvement in Worst Pruritis Numerical Rating Scale score, were also met by both doses of upadacitinib. At week 2 in the Measure Up 1 trial, 38.1% of patients in the 15 mg group and 47.4% of those in the 30 mg group had achieved EASI-75 compared with 3.6% of those in the placebo group. In the Measure Up 2 trial, 33% of the 15 mg group and 44% of the 30 mg group achieved EASI-75 after week 2 compared with 3.6% of those in the placebo group. “The efficacy it shows is unparalleled to any other treatment so far,” Guttman-Yassky said. “It has great efficacy for both the 15 mg and 30 mg doses, and it has quick efficacy. It works within days, and by week 4, you basically reach the maximum efficacy.” Treatment-emergent adverse events were higher in the two treatment groups compared with placebo. Serious adverse events were reported in 2% of the 15 mg cohorts, with 1% and 4% of patients discontinuing treatment. The 30 mg groups had serious adverse events in 3% of patients in both the studies, with 4% and 3% discontinuing treatment. The placebo groups had similar rates, with 3% in each study having a serious adverse event and 4% in each study discontinuing treatment. The possibility of an oral medication becoming available for patients with atopic dermatitis is an exciting one for Guttman-Yassky. “As a treating physician, I really hope to have this drug approved some time this summer,” she said. “For those who do not want an injection or for those who want to see results very quickly, we want to have the ability to treat with JAK inhibitors such as this one that is so efficacious and fast.” Read more about

Vitae Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Vitae Pharmaceuticals founded?

    Vitae Pharmaceuticals was founded in 2001.

  • Where is Vitae Pharmaceuticals's headquarters?

    Vitae Pharmaceuticals's headquarters is located at 502 West Office Center Drive, Fort Washington.

  • What is Vitae Pharmaceuticals's latest funding round?

    Vitae Pharmaceuticals's latest funding round is Acq - P2P.

  • How much did Vitae Pharmaceuticals raise?

    Vitae Pharmaceuticals raised a total of $105.97M.

  • Who are the investors of Vitae Pharmaceuticals?

    Investors of Vitae Pharmaceuticals include Allergan, Oxford Finance, Silicon Valley Bank, Qualifying Therapeutic Discovery Project, New Enterprise Associates and 9 more.

  • Who are Vitae Pharmaceuticals's competitors?

    Competitors of Vitae Pharmaceuticals include Aquinox Pharmaceuticals, Deciphera Pharmaceuticals, VentiRx Pharmaceuticals, Creative Biomolecules, Novus Therapeutics and 13 more.

Compare Vitae Pharmaceuticals to Competitors

R
Resolvyx Pharmaceuticals

Resolvyx Pharmaceuticals offers CombinatoRx which is creating new combination medicines that attack disease on multiple fronts

J
Joyant Pharmaceuticals

Joyant Pharmaceuticals is focused on the development of small molecule therapeutics for cancer and inflammation. Joyant is developing several programs based upon their understanding of the molecular events that control growth, replication and apoptosis.

F
Favrille

Favrille is a developer of cancer and autoimmune disease immuno-therapeutics.

S
Sequoia Pharmaceuticals

Sequoia Pharmaceuticals, Inc. is engaged in the discovery and development of antiviral therapeutics, with a focus on developing new treatments for drug-resistant infectious diseases such as HIV/AIDS and HCV-induced hepatitis. Sequoia Pharmaceuticals is located in Gaithersburg, Md.

P
Prolexys Pharmaceuticals

Prolexys Pharmaceuticals is a developer of cancer and cardiovascular small molecule drugs.

R
Ribozyme Pharmaceuticals

Ribozyme Pharmaceuticals offers RNA-based pharmaceuticals for human disease

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.